局部晚期不可切除的肝内胆管细胞癌患者，经吉西他滨和顺铂化疗后达到病理完全缓解。
A case of unresectable locally advanced intrahepatic cholangiocarcinoma that achieved pathological complete response after gemcitabine and S1 chemotherapy.
机构信息
Department of Surgery, Graduate School of Biomedical and Health Science, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan.
出版信息
Clin J Gastroenterol. 2022 Dec;15(6):1164-1168. doi: 10.1007/s12328-022-01700-x. Epub 2022 Oct 1.
The standard chemotherapy for patients with unresectable cholangiocarcinoma is gemcitabine plus cisplatin, and gemcitabine plus S-1 (GS) chemotherapy is also reported to have similar effectiveness in Japan. However, the response rates of these two chemotherapies were modest, and no patients with intrahepatic cholangiocarcinoma (ICC) have shown a pathological complete response (pCR) following these chemotherapies. We report here the first case of an initially unresectable locally advanced ICC that achieved pCR following GS chemotherapy.
对于无法切除的胆管癌患者，标准的化疗方案是吉西他滨加顺铂，而在日本，吉西他滨加 S-1（GS）化疗也被报道具有相似的疗效。然而，这两种化疗方案的缓解率都不高，而且没有肝内胆管癌（ICC）患者在这些化疗后出现病理完全缓解（pCR）。我们在此报告首例最初无法切除的局部晚期 ICC 患者，在接受 GS 化疗后达到 pCR。
Zotero 插件